<unk>  (TB) vaccines are vaccinations intended for the prevention of<unk> . Immunotherapy as a defence against TB was first proposed in 1890 by Robert Koch. Today, the only effective<unk> in common use is the Bacillus Calmette-Guérin (BCG) vaccine, first used on humans in 1921. About three out of every 10,000 people who get the vaccine experience side effects, which are usually minor except in severely immuno-depressed individuals. While BCG immunization provides fairly effective protection for infants and young children, (including defence against TB meningitis and miliary TB), its efficacy in adults is variable, ranging from 0% to 80%. Several variables have been considered as responsible for the varying outcomes. Demand for TB immunotherapy advancement exists because the disease has become increasingly drug-resistant. Other<unk>  are at various stages of development, including: * MVA85A * rBCG30 * 72F fusion protein * MTBVAC New vaccines are being developed by the<unk> Initiative, including TBVI and Aeras.
Tuberculosis vaccines
Cancer vaccine
Edible vaccines
Malaria vaccine
Anthrax vaccines
Vaccine
Global action plan for influenza vaccines
Typhus vaccine